Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05317507 · ClinicalTrials.gov registry record · Phase 1
Safety of Co-Administered CHI-554 and Alcohol
A Phase 1 study, sponsored by Auburn University.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT05317507 is a Phase 1 study that has completed, run by Auburn University. The registered enrollment target is 29 participants.
The verdict
NCT05317507, a Phase 1 study, has completed, sponsored by Auburn University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
This is a Phase 1, randomized, double-blind study to assess the safety, tolerability, and effects of CHI-554 when co-administered with alcohol.
Interventions
- DRUG Placebo
- DRUG CBD oil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2022-05-09 |
| Est. Completion | 2023-03-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05317507
The ClinicalTrials.gov registry entry for NCT05317507 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Auburn University, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05317507 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05317507 about?
NCT05317507 is a clinical study titled "Safety of Co-Administered CHI-554 and Alcohol". This is a Phase 1, randomized, double-blind study to assess the safety, tolerability, and effects of CHI-554 when co-administered with alcohol.
What is the current status of trial NCT05317507?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2022-05-09. Estimated completion is 2023-03-31.
What interventions are being tested in trial NCT05317507?
The interventions under investigation include: Placebo (DRUG), CBD oil (DRUG).
Who is sponsoring clinical trial NCT05317507?
This trial is sponsored by Auburn University, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.